Zymeworks Invited to Present at Leading Antibody Biology and Engineering Conference

March 15, 2012

VANCOUVER, British Columbia, Canada – Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, today announced that it had been invited to present its recent advances in the field of bispecific therapeutic antibodies at the Gordon Research Conferences’ second Antibody Biology and Engineering conference in Galveston, Texas.

Dr. Thomas Spreter Von Kreudenstein, Senior Scientist, Protein Engineering will be highlighting Zymeworks’ successful Azymetric™ platform, which was the focus of a strategic collaboration with Merck in 2011. Dr. Spreter Von Kreudenstein’s presentation, “Optimized Fc Heterodimers for Improved Purity and Stability in the Development of Bispecific Antibodies” will be held on Wednesday, March 28th at 12:10 PM.

“The Gordon Research Conferences represent the world's premier scientific conferences, where leading pharmaceutical and academic investigators from around the globe discuss their latest work and future challenges,” says Dr. Surjit Dixit, Zymeworks’ Chief Technology Officer. “We believe that an invitation by the conference chairs, Dr. Paul Carter, the current head of antibody engineering at Genentech, and Dr. Derry Roopenian from the Jackson Laboratory, is further validation that Zymeworks’ Azymetric™ platform has significantly advanced the field of heterodimeric bispecific antibody therapeutics.”

About Zymeworks Inc.

Zymeworks is a privately held biotechnology company that is developing best-in-class antibody therapeutics for the treatment of oncology, autoimmunity and inflammatory diseases. The company’s proprietary ZymeCAD™ structure-guided protein engineering technology and its novel Azymetric™ and AlbuCORE™ platforms enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on growing its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. More information on Zymeworks can be found at http://www.zymeworks.com.

About the Gordon Research Conferences

The Gordon Research Conferences were initiated by Dr. Neil E. Gordon, of the Johns Hopkins University, who recognized in the late 1920s the difficulty in establishing good, direct communication between scientists. The Gordon Research Conferences promote discussions and the free exchange of ideas at the research frontiers of the biological, chemical and physical sciences. Scientists with common professional interests come together for a full week of intense discussion and examination of the most advanced aspects of their field. Each Conference operates relatively autonomously with each Conference Chair being completely responsible for the content and conduct of the meeting as well as the selection of discussion leaders and attendees. More information on the Gordon Research Conferences can be found at http://www.grc.org.


Zymeworks Inc.
David Poon, Ph.D.
Associate Director, BD


Zymeworks Inc.